🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Pfizer Falls on Deal With UN-Backed Body to Sell Covid Drug Sans Royalty

Published 11/16/2021, 07:28 AM
Updated 11/16/2021, 07:29 AM
© Reuters
MRK
-
PFE
-
POOL
-
REGN
-

By Dhirendra Tripathi

Investing.com – Pfizer stock (NYSE:PFE) fell more than 1% in Tuesday’s premarket trade after the company said it will sell its Covid-19 oral drug in low- and middle-income countries without earning royalties as long as the World Health Organization keeps the pandemic classified as a public health emergency of international concern.

Pfizer has signed a licensing pact with UN-backed public health organization called Medicines Patent Pool (NASDAQ:POOL), to expand access for the oral medicine in low- and middle-income countries.

Under the deal, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply the medicine, covering up to approximately 53% of the world’s population.

The drug was expected to be another money-spinner for the pharmaceutical giant after the success of its Covid-19 vaccine, providing a second line of defense against the disease for health authorities and a second pillar of income for the company.

MPP has already invited expressions of interest from parties to manufacture and sell the co-pack containing the drug, scientifically known as PF-07321332, as well as ritonavir, the HIV drug that has to be jointly given under the prescribed treatment.

The pill, which is still awaiting regulatory approval, is one of only three oral medicines so far to prove their efficacy against Covid-19, along with treatments from Merck (NYSE:MRK) and Regeneron (NASDAQ:REGN). Pfizer claims to reduce the risk of hospitalization or death by 89%. Merck's (NYSE:MRK) molnupiravir, boasts an efficacy ratio of just over 50%.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.